Faron Pharmaceuticals Oy (GB:FARN) has released an update.
Faron Pharmaceuticals Oy successfully completed a substantial share offering, raising EUR 30.7 million to fund its strategic initiatives, including the advancement of its BEXMAB clinical trial and preparation for Phase III drug development. The offering, which was oversubscribed, saw the allocation of new shares to both existing shareholders and new investors, reinforcing the company’s financial stability through March 2025. This financial boost will also enable Faron to seek FDA advice and explore potential licensing or partnership agreements for its bexmarilimab drug.
For further insights into GB:FARN stock, check out TipRanks’ Stock Analysis page.
